MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 576795 | Name: Plafibride HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Plafibride is an acyl derivative of morpholinomethylurea (MMU) with clofibric acid. Plafibride is hypolipemic, platelet aggregation inhibiting agent. In the rat, plafibride inhibited significantly the spontaneously formed circulating platelet aggregates. In vitro plafibride appeared as an effective antiaggregant agent although less powerful than morpholinomethylurea, one of its presumed metabolites.

Chemical Structure

Plafibride HCl
Plafibride HCl
CAS#65285-81-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 576795

Name: Plafibride HCl

CAS#: 65285-81-6 (HCl)

Chemical Formula: C16H22ClN3O4

Exact Mass: 355.1299

Molecular Weight: 355.82

Elemental Analysis: C, 54.01; H, 6.23; Cl, 9.96; N, 11.81; O, 17.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
65285-81-6 (HCl) 63394-05-8 (free base) 67924-59-8 (deleted)
Synonym
Plafibride; Idonor; ITA 104; ITA-104; ITA104; Perifunal;
IUPAC/Chemical Name
2-(4-chlorophenoxy)-2-methyl-N-((morpholinomethyl)carbamoyl)propanamide
InChi Key
DDDQVDIPBFGVIG-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H22ClN3O4/c1-16(2,24-13-5-3-12(17)4-6-13)14(21)19-15(22)18-11-20-7-9-23-10-8-20/h3-6H,7-11H2,1-2H3,(H2,18,19,21,22)
SMILES Code
CC(C)(Oc1ccc(Cl)cc1)C(=O)NC(=O)NCN2CCOCC2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 355.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Filip M, Păduraru I, Nechifor M, Dănilă GH, Popovici I, Filip FM, Poşircă F. Explorarea acţiuni unui derivat al acidului fibric asupra metabolismului lipidic [The action of a fibric acid derivative on lipid metabolism]. Rev Med Chir Soc Med Nat Iasi. 1989 Jul-Sep;93(3):573-6. Romanian. PMID: 2636755. 2: Dănilă G, Nechifor M, Filip M, Păduraru I, Ifrim C, Grădinariu D, Papa V, Manolescu A, Bădescu A. Derivat al acidului clofibric cu acţiune hipolipemiantă şi antiagregantă plachetară [A clofibric acid derivative with hypolipemic and platelet antiaggregant action]. Rev Med Chir Soc Med Nat Iasi. 1988 Jan- Mar;92(1):127-32. Romanian. PMID: 3393745. 3: Rodriguez F, López IM, Jover E. Plafibride treatment and serum lipids in hyperlipoproteinemias. J Med. 1987;18(3-4):153-63. PMID: 3323393. 4: Joven J. Plafibride es un fármaco eficaz como hipolipemiante? [Plafibride--is it an effective drug as a hypolipemic agent?]. Med Clin (Barc). 1985 Apr 20;84(15):632. Spanish. PMID: 3999857. 5: Soringer Escofet FJ, Esteva de Antonio I. Plafibride e insuficiencia vascular de miembros inferiores [Plafibride and vascular insufficiency of the lower limbs]. Med Clin (Barc). 1985 Apr 20;84(15):632. Spanish. PMID: 3999856. 6: Lázaro Campillo T, Gesto Castromil R, de la Sierra L, Pujadas J, Villafana W, Moreno R. Terapéutica de la insuficiencia vascular de miembros inferiores con plafibride [Therapy of vascular insufficiency of the legs with plafibride]. Med Clin (Barc). 1984 Dec 1;83(18):752-5. Spanish. PMID: 6521538. 7: Palou Monzo J, López-Delmás FJ. Terapeutica de las úlceras isquémicas de las extremidades inferiores con plafibride [Therapy of ischemic ulcers of the lower extremities using plafibride]. Angiologia. 1984 Nov-Dec;36(6):273-8. Spanish. PMID: 6517385. 8: Soler J, Vinzia C, Gómez JM, Morató J. Tratamiento con plafibride de las hiperlipidemias tipo II y IV [Plafibride treatment of hyperlipidemias type II and IV]. Med Clin (Barc). 1984 May 19;82(19):840-2. Spanish. PMID: 6738212. 9: Calatayud JM. Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain. Methods Find Exp Clin Pharmacol. 1983 Dec;5(10):707-14. PMID: 6672489. 10: Badimón JJ, Padró T, Cánovas M, Vidal M, Villaverde CA. Hypolipemic profile of plafibride in a model of experimental atherosclerosis. Methods Find Exp Clin Pharmacol. 1983 Nov;5(9):613-7. PMID: 6668971. 11: Vilageliu J, Freixes J, Bruseghini L. Activity of plafibride on erythrocyte deformability. Arzneimittelforschung. 1983;33(3):401-4. PMID: 6683514. 12: Lasierra J, Díez MM, Fernández A, Viladés E, Gil M, Velázquez E. Valoración del efecto del plafibride y del acetil salicilato de lisina en la producción de PGI2 [Evaluation of the effects of plafibride and lysine acetyl salicylate on the production of PGI2]. Sangre (Barc). 1983;28(6):687-95. Spanish. PMID: 6424250. 13: Ferreira Montero IJ, Gutiérrez Martín M, del Río Ligorit A, Casasnovas Lenguas JA, Cornudella Lacasa R. Estudio de la actividad del plafibride en el tratamiento de la hiperlipoproteinemia tipo IV [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)]. Med Clin (Barc). 1982 May 1;78(9):380-5. Spanish. PMID: 7047926. 14: Demichelis Genesio MA, Bracons R, Vicens B, Zapatero J, Bruseghini L. Clinical trials of plafibride in geriatric patients. Arzneimittelforschung. 1981;31(10a):1852-5. PMID: 7198465. 15: Santaniello E, Conti F, Vilageliu J, Bruseghini L. Bioavailability of plafibride in healthy volunteers. Arzneimittelforschung. 1981;31(10a):1850-2. PMID: 7198464. 16: Dalmau J, Vicens B, Zapatero J, Bruseghini L. Plafibride tolerance trial in healthy volunteers. Arzneimittelforschung. 1981;31(10a):1845-9. PMID: 7198463. 17: Dalmau J, Vicens B, Zapatero J, Bruseghini L. Plafibride tolerance trial at increasing doses in healthy volunteers. Arzneimittelforschung. 1981;31(10a):1840-4. PMID: 7198462. 18: Zapatero J, Basi N, Vilageliu J, Sanfeliu C, Bruseghini L. Toxicological studies of plafibride. Part 4: Interaction of plafibride with other drugs. Arzneimittelforschung. 1981;31(10a):1835-8. PMID: 7198461. 19: Sanfeliu C, Zapatero J, Bruseghini L. Toxicological studies of plafibride. Part 3: Study of teratogenic activity in rats and rabbits. Arzneimittelforschung. 1981;31(10a):1831-4. PMID: 7198460. 20: Zapatero J, Sanfeliu C, Bruseghini L. Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs. Arzneimittelforschung. 1981;31(10a):1819-30. PMID: 7198459.